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The authors describe a case of neuroleptic malignant syndrome that occurred in a patient on
amitriptyline and lithium carbonate. They suggest that lithium-antidepressant combination can
precipitate this syndrome. Intestinal pseudo-obstruction was a prominent feature in the patient in
this study.
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INRODUCTION
A 61-year-old male with a 12 year history of bipolar
affective disorder presented with an acute hypomanic relapse
(corresponding to 296.2 of the ICD-9 part V classification).
He had received neuroleptics on several previous occasions,
had no other medical disorder, and had normal results from
liver function tests. He was admitted to a psychiatric hospital
and was started on chlorpromazine 25 mg tds. Seven days
later, when his hypomanic manifestations had subsided,
chlorpromazine was stopped and amitriptyline 25 mg tds and
lithium carbonate 300 mg tds were started. After another
week, he was transferred to St. Luke's Hospital with impaired
consciousness, a pyrexia of 39.5°C, extreme rigidity of the
limbs, neck and abdominal muscles, as well as prominent
cogwheeling at the wrists. The abdomen was distended and
tympanitic; bowel sounds were sluggish. A plain X-ray con-
firmed gaseous distension of the small and large intestines.
A peak creatine kinase activity of 715 gl was reached
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24 hours after admission. Serum chlorpromazine level was
undetectable on admission. CT scan ofthe brain was normal.
The patient was started on bromocriptine, a levodopa-
carbidopa combination, and low-dose subcutaneous heparin.
Abdominal distension resolved completely within 20 hours,
the level ofconsciousness returned to normal within 24 hours,
and core temperature returned to normal within 30 hours.
Colonoscopy was normal.
Neuroleptic malignant syndrome (NMS) is an idiosyn-
cratic, potentially fatal reaction to neuroleptics with an esti-
mated incidence of 1.4% (Pope et al 1986). It usually
develops while the patient is on neuroleptics. In the patient
in this study, NMS occurred seven days after stopping
neuroleptics (no depot preparations were used) and starting
lithium therapy. Susman and Addonizio (1987) have reported
a case of reinduction ofNMS with lithium. However, other
authors (Baastrup et al 1976; Deng et al 1990) have found no
association ofNMS to lithium therapy. There have also been
reports ofa possible association oflithium toNMS in patients
with Parkinson's disease (Pfeiffer and Suscha 1985; Koehler
and Mirandolle 1988). Tricyclic antidepressants can rarely
cause NMS (Baca and Martinelli 1990). This report
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postulates that lithium-antidepressant combination can pre-
cipitate NMS, especially in those patients who are, or have
recently been, on neuroleptics. It is possible that lithium
predisposes to NMS by enhancing the dopamine-blocking
action of neuroleptics. It should be noted that NMS has
occurred with drugs such as clozapine that normally have
minimal extrapyramidal effects (Redding et al 1993; Miller
et al 1991).
The patient in this study had intestinal pseudo-obstruction
as a prominent feature. To the knowledge ofthe authors, this
condition has not been previously described in NMS.
Although it is possible to attribute its occurrence to the
administration of amitriptyline, its course closely paralleled
the other features of NMS. This finding suggests that the
obstruction is part of the generalized autonomic nervous
system dysfunction ofNMS.
Finally, the patient responded favorably to treatment
which consisted of bromocriptine and a levodopa-carbidopa
combination. Subcutaneous heparin was used in order to
minimize the risk ofthromboembolism in view ofprolonged
immobilization.
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